

Fourth Hanseatic India Colloquium


October 30th, 2009




Evotec's Mission: Develop best-in-class *differentiated* therapeutics & deliver a superior Discovery Alliances Business



Discovery Alliance Business (DAB) is „CORE BUSINESS“




Three core strategic elements drive growth to 2014



Leveraging baseline business with increased capabilities,
Evotec assets, know-how and cost arbitrage

Leveraging our offering with Asian capacities accelerates our Drug Discovery leadership position

1 What it takes to lead the Drug Discovery market



The right step to grow without taking too large M&A risk

1 Why RSIL* / DIL** – what do we acquire to build Evotec India?

Background on the company

- Headcount 164, >140 highly qualified scientific staff
- Office and operations in Thane, Mumbai
- 7 synthesis labs, 1 analytical lab, existing library synthesis business***
- Solid ongoing business ~€2m revenues

The transaction

- Evotec to purchase 70% of RSIL shares from DIL** for **ca. €2,8** in cash – the consideration includes a potential earn-out
- Evotec to take full control of operational business
- Evotec owns call option for remaining 30%



* Research Support International Ltd.

** DIL Ltd. (listed on Bombay Stock Exchange)

*** Already existing joint venture with Evotec

Excellent people and facilities to leverage DAB offering

1 Evotec India



Library Synthesis and Management : Facility



Development Chemistry Lab – Reactors



Analytical Lab



Chemical Support Service




Licenses & Registrations



Medchem Support Services Lab

Acquisition follows our strategy to grow – Building on strength of Discovery Alliance Business

1 DAB strategy



* Fragment based drug discovery

Caveats

- Restricted capital market
 - Internal loan
- Bureaucracy
 - Name change
- English language
- Efficiency

